H. Lundbeck AS (FRA:LDBB) Debt-to-Equity : 0.19 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Debt-to-Equity?

H. Lundbeck AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €11 Mil. H. Lundbeck AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €547 Mil. H. Lundbeck AS's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €3,009 Mil. H. Lundbeck AS's debt to equity for the quarter that ended in Mar. 2024 was 0.19.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for H. Lundbeck AS's Debt-to-Equity or its related term are showing as below:

FRA:LDBB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.25 Max: 0.77
Current: 0.19

During the past 13 years, the highest Debt-to-Equity Ratio of H. Lundbeck AS was 0.77. The lowest was 0.01. And the median was 0.25.

FRA:LDBB's Debt-to-Equity is ranked better than
60.68% of 847 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs FRA:LDBB: 0.19

H. Lundbeck AS Debt-to-Equity Historical Data

The historical data trend for H. Lundbeck AS's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Debt-to-Equity Chart

H. Lundbeck AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.57

0.47

0.29

0.27

0.19

H. Lundbeck AS Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.25	0.23	0.19	0.19	0.19

Competitive Comparison of H. Lundbeck AS's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

H. Lundbeck AS's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's Debt-to-Equity falls into.

H. Lundbeck AS Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

H. Lundbeck AS's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(11.538	+	545.386)	/	2957.697
	=	0.19

H. Lundbeck AS's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(11.4	+	546.92)	/	3008.863
	=	0.19

H. Lundbeck AS (FRA:LDBB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

H. Lundbeck AS Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

H. Lundbeck AS (FRA:LDBB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (FRA:LDBB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

HLBBF:USA HLUBF:USA 0ABR:UK 0ND5:UK HLUN A:Denmark HLUN B:Denmark LDBA:Germany

Address

Ottiliavej 9, Valby, DNK, 2500

Website

https://www.lundbeck.com

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS (FRA:LDBB) Headlines

No Headlines